{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:09:15Z","timestamp":1792440555303,"version":"4.5.0"},"reference-count":142,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671889, 81703578, 81800594"],"award-info":[{"award-number":["81671889, 81703578, 81800594"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2019QNA7032"],"award-info":[{"award-number":["2019QNA7032"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.00786","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T12:33:36Z","timestamp":1590755616000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":111,"title":["Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy"],"prefix":"10.3389","volume":"11","author":[{"given":"Lu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhe","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqi","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haili","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishan","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1053\/j.ajkd.2013.08.015","article-title":"Pharmacokinetics and pharmacodynamics of imipenem and meropenem in critically ill patients treated with continuous venovenous hemodialysis","volume":"63","author":"Afshartous","year":"2014","journal-title":"Am. J. Kidney Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13054-019-2434-5","article-title":"Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration","volume":"23","author":"Aguilar","year":"2019","journal-title":"Crit. Care"},{"key":"B3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40780-015-0031-6","article-title":"Pk\/pd analysis of biapenem in patients undergoing continuous hemodiafiltration","volume":"1","author":"Akashita","year":"2015","journal-title":"J. Pharm. Health Care Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/jac\/dkt304","article-title":"Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic\/pharmacodynamic analysis","volume":"69","author":"Asin-Prieto","year":"2014","journal-title":"J. Antimicrob Chemother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jcrc.2018.11.016","article-title":"Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: influence of residual renal function on pk\/pd target attainment","volume":"50","author":"Barrasa","year":"2019","journal-title":"J. Crit. Care"},{"key":"B6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/bf02425056","article-title":"Clinical use of ganciclovir during renal failure and continuous hemodialysis","volume":"20","author":"Bastien","year":"1994","journal-title":"Intensive Care Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1592\/phco.30.10.1016","article-title":"Peramivir pharmacokinetics in two critically ill adults with 2009 h1n1 influenza a concurrently receiving continuous renal replacement therapy","volume":"30","author":"Bazan","year":"2010","journal-title":"Pharmacotherapy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/jac\/dkg139","article-title":"Amphotericin b lipid formulations in critically ill patients on continuous veno-venous haemofiltration","volume":"51","author":"Bellmann","year":"2003","journal-title":"J. Antimicrob Chemother."},{"key":"B9","first-page":"243","article-title":"Teicoplanin pharmacokinetics in critically ill patients on continuous veno-venous hemofiltration","volume":"48","author":"Bellmann","year":"2010","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s00134-017-4755-7","article-title":"Acute kidney injury in sepsis","volume":"43","author":"Bellomo","year":"2017","journal-title":"Intensive Care Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.5414\/CP202161","article-title":"Peramivir pharmacokinetics in a patient receiving continuous veno-venous hemodiafiltration during the 2009 h1n1 influenza a pandemic","volume":"52","author":"Bentley","year":"2014","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1093\/jac\/dkt261","article-title":"A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy","volume":"68","author":"Beumier","year":"2013","journal-title":"J. Antimicrob Chemother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"R105","DOI":"10.1186\/cc13886","article-title":"Beta-lactam antibiotic concentrations during continuous renal replacement therapy","volume":"18","author":"Beumier","year":"2014","journal-title":"Crit. Care"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1128\/AAC.01582-09","article-title":"Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration","volume":"54","author":"Bilgrami","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1053\/j.ackd.2008.04.004","article-title":"Renal replacement therapy in acute kidney injury: intermittent versus continuous? How much is enough","volume":"15","author":"Bouchard","year":"2008","journal-title":"Adv. Chronic Kidney Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1002\/phar.1866","article-title":"Pharmacokinetics of imipenem\/cilastatin burn intensive care unit patients undergoing high-dose continuous venovenous hemofiltration","volume":"36","author":"Boucher","year":"2016","journal-title":"Pharmacotherapy"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00134-006-0397-x","article-title":"Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing","volume":"32","author":"Bouman","year":"2006","journal-title":"Intensive Care Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1002\/phar.1744","article-title":"Ceftolozane\/tazobactam pharmacokinetics in a critically ill adult receiving continuous renal replacement therapy","volume":"36","author":"Bremmer","year":"2016","journal-title":"Pharmacotherapy"},{"key":"B19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s13054-018-2278-4","article-title":"Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study","volume":"22","author":"Broeker","year":"2018","journal-title":"Crit. Care"},{"key":"B20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/2110-5820-4-13","article-title":"Cotrimoxazole - optimal dosing in the critically ill","volume":"4","author":"Brown","year":"2014","journal-title":"Ann. Intensive Care"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1093\/jac\/dky370","article-title":"Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections","volume":"73","author":"Burger","year":"2018","journal-title":"J. Antimicrob Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ijantimicag.2015.05.020","article-title":"Population pharmacokinetics and dosing simulations of cefepime in septic shock patients receiving continuous renal replacement therapy","volume":"46","author":"Carlier","year":"2015","journal-title":"Int. J. Antimicrob Agents"},{"key":"B23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijantimicag.2011.04.010","article-title":"Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients","volume":"38","author":"Chaijamorn","year":"2011","journal-title":"Int. J. Antimicrob Agents"},{"key":"B24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000455897","article-title":"Ex vivo ceftolozane\/tazobactam clearance during continuous renal replacement therapy","volume":"44","author":"Chaijamorn","year":"2017","journal-title":"Blood Purif"},{"key":"B25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40560-018-0330-8","article-title":"Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy: a monte carlo simulation study","volume":"6","author":"Chaijamorn","year":"2018","journal-title":"J. Intensive Care"},{"key":"B26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jcrc.2019.07.008","article-title":"Optimal vancomycin dosing regimens for critically ill patients with acute kidney injury during continuous renal replacement therapy: a monte carlo simulation study","volume":"54","author":"Charoensareerat","year":"2019","journal-title":"J. Crit. Care"},{"key":"B27","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/phar.1526","article-title":"Therapeutic drug monitoring of continuous-infusion acylovir for disseminated herpes simplex virus infection in a neonate receiving concurrent extracorporeal life support and continuous renal replacement therapy","volume":"35","author":"Cies","year":"2015","journal-title":"Pharmacotherapy"},{"key":"B28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000353400","article-title":"Pharmacokinetics of daily daptomycin in critically ill patients undergoing continuous renal replacement therapy","volume":"59","author":"Corti","year":"2013","journal-title":"Chemotherapy"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1345\/aph.1P160","article-title":"Trimethoprim\/sulfamethoxazole pharmacokinetics in two patients undergoing continuous venovenous hemodiafiltration","volume":"44","author":"Curkovic","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"386","DOI":"10.4103\/0970-9185.98357","article-title":"Renal replacement therapy in icu","volume":"28","author":"Deepa","year":"2012","journal-title":"J. Anaesthesiol Clin. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/phar.1151","article-title":"Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and\/or extracorporeal membrane oxygenation","volume":"32","author":"Eyler","year":"2012","journal-title":"Pharmacotherapy"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1128\/AAC.02090-12","article-title":"Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration","volume":"58","author":"Eyler","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1128\/AAC.49.6.2421-2428.2005","article-title":"Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients","volume":"49","author":"Fish","year":"2005","journal-title":"Antimicrob Agents Chemother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/jac\/dkh421","article-title":"Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration","volume":"54","author":"Fuhrmann","year":"2004","journal-title":"J. Antimicrob Chemother."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1542\/peds.2014-3380","article-title":"Therapeutic drug monitoring in neonatal hsv infection on continuous renal replacement therapy","volume":"136","author":"Funaki","year":"2015","journal-title":"Pediatrics"},{"key":"B36","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00228-016-2045-x","article-title":"Pharmacokinetics of cefoperazone\/sulbactam in critically ill patients receiving continuous venovenous hemofiltration","volume":"72","author":"Gao","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1128\/AAC.01733-10","article-title":"Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients","volume":"55","author":"Garonzik","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"B38","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/cc13803","article-title":"Treatment with echinocandins during continuous renal replacement therapy","volume":"18","author":"Gonzalez","year":"2014","journal-title":"Crit. Care"},{"key":"B39","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1515\/jbcpp-2016-0022","article-title":"Pharmacokinetics of ceftriaxone in patients undergoing continuous renal replacement therapy","volume":"27","author":"Goto","year":"2016","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13613-020-00666-8","article-title":"Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study","volume":"10","author":"Grensemann","year":"2020","journal-title":"Ann. Intensive Care"},{"key":"B41","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/0.1mat.0000225268.28044.ae","article-title":"Pharmacokinetics and the most suitable regimen of panipenem\/beta mipron in critically ill patients receiving continuous renal replacement therapy: a pilot study","volume":"52","author":"Hayakawa","year":"2006","journal-title":"Asaio J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1592\/phco.29.5.562","article-title":"Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis","volume":"29","author":"Heintz","year":"2009","journal-title":"Pharmacotherapy"},{"key":"B43","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1248\/yakushi.130.87","article-title":"Doripenem pharmacokinetics in critically ill patients receiving continuous hemodiafiltration (chdf)","volume":"130","author":"Hidaka","year":"2010","journal-title":"Yakugaku Zasshi"},{"key":"B44","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000504039","article-title":"In vitro evaluation of linezolid and doripenem clearance with different hemofilters","volume":"49","author":"Hiraiwa","year":"2020","journal-title":"Blood Purif."},{"key":"B45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/1060028019865873","article-title":"Antibiotic dosing for critically ill adult patients receiving intermittent hemodialysis, prolonged intermittent renal replacement therapy, and continuous renal replacement therapy: an update","volume":"54","author":"Hoff","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"B46","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1159\/000363495","article-title":"Continuous renal replacement therapy-related strategies to avoid colistin toxicity: a clinically orientated review","volume":"37","author":"Honore","year":"2014","journal-title":"Blood Purif."},{"key":"B47","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1128\/AAC.00892-13","article-title":"Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients","volume":"58","author":"Horvatits","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"B48","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.ijantimicag.2018.01.021","article-title":"Population pharmacokinetics\/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy","volume":"51","author":"Ide","year":"2018","journal-title":"Int. J. Antimicrob Agents"},{"key":"B49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10156-007-0572-1","article-title":"Pharmacokinetic modeling and dosage adaptation of biapenem in japanese patients during continuous venovenous hemodiafiltration","volume":"14","author":"Ikawa","year":"2008","journal-title":"J. Infect. Chemother."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1177\/0091270005280583","article-title":"Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients","volume":"45","author":"Isla","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2165\/00003088-200847030-00003","article-title":"Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy","volume":"47","author":"Isla","year":"2008","journal-title":"Clin. Pharmacokinet"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1097\/CCM.0000000000000317","article-title":"The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*","volume":"42","author":"Jamal","year":"2014","journal-title":"Crit. Care Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ijantimicag.2015.02.014","article-title":"Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration","volume":"46","author":"Jamal","year":"2015","journal-title":"Int. J. Antimicrob Agents"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e863","DOI":"10.1097\/CCM.0000000000003955","article-title":"Antibiotic exposure profiles in trials comparing intensity of continuous renal replacement therapy","volume":"47","author":"Jang","year":"2019","journal-title":"Crit. Care Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2147\/TCRM.S59187","article-title":"Effectiveness of pharmacist dosing adjustment for critically ill patients receiving continuous renal replacement therapy: a comparative study","volume":"10","author":"Jiang","year":"2014","journal-title":"Ther. Clin. Risk Manag."},{"key":"B56","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ijantimicag.2016.06.008","article-title":"Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration","volume":"48","author":"Karaiskos","year":"2016","journal-title":"Int. J. Antimicrob Agents"},{"key":"B57","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1128\/AAC.00985-12","article-title":"Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration","volume":"57","author":"Karvanen","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"B58","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.jiac.2015.02.011","article-title":"Pharmacokinetics and dosing estimation of meropenem in japanese patients receiving continuous venovenous hemodialysis","volume":"21","author":"Kawano","year":"2015","journal-title":"J. Infect. Chemother."},{"key":"B59","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000368884","article-title":"Trimethoprim and sulfamethoxazole transmembrane clearance during modeled continuous renal replacement therapy","volume":"38","author":"Kesner","year":"2014","journal-title":"Blood Purif"},{"key":"B60","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13054-015-0753-8","article-title":"Evaluation of sulfobutylether-beta-cyclodextrin (sbecd) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy","volume":"19","author":"Kiser","year":"2015","journal-title":"Crit. Care"},{"key":"B61","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/CPAA.S127502","article-title":"Pharmacokinetics and outcome of tazobactam\/piperacillin in japanese patients undergoing low-flow continuous renal replacement therapy: dosage considerations","volume":"9","author":"Kohama","year":"2017","journal-title":"Clin. Pharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ijantimicag.2016.06.005","article-title":"Treatment of multidrug-resistant pseudomonas aeruginosa with ceftolozane\/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration","volume":"48","author":"Kuti","year":"2016","journal-title":"Int. J. Antimicrob Agents"},{"key":"B63","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40121-013-0012-8","article-title":"Amikacin pharmacokinetics during continuous veno-venous hemodialysis","volume":"2","author":"Lam","year":"2013","journal-title":"Infect. Dis. Ther."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00134-008-1034-7","article-title":"Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy","volume":"34","author":"Langgartner","year":"2008","journal-title":"Intensive Care Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00134-010-1882-9","article-title":"Oseltamivir carboxylate accumulation in a patient treated by haemodiafiltration and extracorporeal membrane oxygenation","volume":"36","author":"Lemaitre","year":"2010","journal-title":"Intensive Care Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/FTD.0b013e318248672c","article-title":"Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (h1n1) influenza","volume":"34","author":"Lemaitre","year":"2012","journal-title":"Ther. Drug Monit"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e1918","DOI":"10.1128\/AAC.01957-18","article-title":"Multicenter population pharmacokinetic study of colistimethate sodium and colistin dosed as in normal renal function in patients on continuous renal replacement therapy","volume":"63","author":"Leuppi-Taegtmeyer","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"B68","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ijantimicag.2018.10.006","article-title":"Population pharmacokinetics and simulations of imipenem in critically ill patients undergoing continuous renal replacement therapy","volume":"53","author":"Li","year":"2019","journal-title":"Int. J. Antimicrob Agents"},{"key":"B69","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1128\/AAC.49.11.4814-4815.2005","article-title":"Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration","volume":"49","author":"Li","year":"2005","journal-title":"Antimicrob Agents Chemother."},{"key":"B70","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00228-019-02755-5","article-title":"Pharmacokinetics of and maintenance dose recommendations for vancomycin in severe pneumonia patients undergoing continuous venovenous hemofiltration with the combination of predilution and postdilution","volume":"76","author":"Li","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"e162","DOI":"10.1002\/phar.1470","article-title":"Fluconazole pharmacokinetics in a morbidly obese, critically ill patient receiving continuous venovenous hemofiltration","volume":"34","author":"Lopez","year":"2014","journal-title":"Pharmacotherapy"},{"key":"B72","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1053\/j.ajkd.2016.03.427","article-title":"Continuous dialysis therapies: core curriculum 2016","volume":"68","author":"Macedo","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"B73","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jgar.2020.03.003","article-title":"Clinical pharmacokinetics of ceftolozane and tazobactam in an obese patient receiving continuous venovenous haemodiafiltration: a patient case and literature review","volume":"21","author":"Mahmoud","year":"2020","journal-title":"J. Glob Antimicrob Resist."},{"key":"B74","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1128\/AAC.45.10.2949-2954.2001","article-title":"Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients","volume":"45","author":"Malone","year":"2001","journal-title":"Antimicrob Agents Chemother."},{"key":"B75","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ijantimicag.2013.06.011","article-title":"Pharmacokinetics of amphotericin b lipid complex in critically ill patients undergoing continuous venovenous haemodiafiltration","volume":"42","author":"Malone","year":"2013","journal-title":"Int. J. Antimicrob Agents"},{"key":"B76","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10156-013-0599-4","article-title":"Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the japanese society of chemotherapy and the japanese society of therapeutic drug monitoring","volume":"19","author":"Matsumoto","year":"2013","journal-title":"J. Infect. Chemother."},{"key":"B77","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijantimicag.2010.10.003","article-title":"Ganciclovir pharmacokinetics and suggested dosing in continuous venovenous haemodiafiltration","volume":"37","author":"McGloughlin","year":"2011","journal-title":"Int. J. Antimicrob Agents"},{"key":"B78","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000484974","article-title":"Modified colistin regimen for critically ill patients with acute renal impairment and continuous renal replacement therapy","volume":"63","author":"Menna","year":"2018","journal-title":"Chemotherapy"},{"key":"B79","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000070997","article-title":"How to calculate clearance of highly protein-bound drugs during continuous venovenous hemofiltration demonstrated with flucloxacillin","volume":"26","author":"Meyer","year":"2003","journal-title":"Kidney Blood Press Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1159\/000501632","article-title":"Evaluation of proteins and cells that adsorb to dialysis membranes used in continuous hemodiafiltration: comparison of an69st, polymethylmethacrylate, and polysulfone membranes","volume":"48","author":"Michikoshi","year":"2019","journal-title":"Blood Purif"},{"key":"B81","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1128\/aac.48.2.369-377.2004","article-title":"Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus mic","volume":"48","author":"Mueller","year":"2004","journal-title":"Antimicrob Agents Chemother."},{"key":"B82","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s43440-019-00056-3","article-title":"Concentration of meropenem in patients with sepsis and acute kidney injury before and after initiation of continuous renal replacement therapy: a prospective observational trial","volume":"72","author":"Nowak-Kozka","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1248\/yakushi.131.1395","article-title":"Effect of hemopurification rate on doripenem pharmacokinetics in critically ill patients receiving high-flow continuous hemodiafiltration","volume":"131","author":"Ohchi","year":"2011","journal-title":"Yakugaku Zasshi"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1128\/AAC.02608-15","article-title":"Ceftolozane-tazobactam pharmacokinetics in a critically ill patient on continuous venovenous hemofiltration","volume":"60","author":"Oliver","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"B85","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jsps.2014.08.005","article-title":"Vancomycin therapy in critically ill patients on continuous renal replacement therapy; Are we doing enough","volume":"23","author":"Omrani","year":"2015","journal-title":"Saudi Pharm. J."},{"key":"B86","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10047-019-01139-x","article-title":"Comparison of adsorption of selected antibiotics on the filters in continuous renal replacement therapy circuits: in vitro studies","volume":"23","author":"Onichimowski","year":"2020","journal-title":"J. Artif. Organs."},{"key":"B87","doi-asserted-by":"crossref","DOI":"10.1007\/s43440-020-00104-3","article-title":"Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial","volume-title":"Pharmacol. Rep.","author":"Onichimowski","year":"2020"},{"key":"B88","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/FTD.0000000000000641","article-title":"Fluconazole exposure in plasma and bile during continuous venovenous hemodialysis","volume":"41","author":"Oualha","year":"2019","journal-title":"Ther. Drug Monit"},{"key":"B89","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.ajkd.2013.02.349","article-title":"Kdoqi us commentary on the 2012 kdigo clinical practice guideline for acute kidney injury","volume":"61","author":"Palevsky","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"B90","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1128\/AAC.00424-11","article-title":"Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using monte carlo simulations to predict doses for specified pharmacodynamic targets","volume":"55","author":"Patel","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"B91","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2165\/00003088-200746120-00003","article-title":"Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy","volume":"46","author":"Pea","year":"2007","journal-title":"Clin. Pharmacokinet"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/phar.2332","article-title":"Pharmacokinetics and pharmacodynamics of extended-infusion cefepime in critically ill patients receiving continuous renal replacement therapy: a prospective, open-label study","volume":"39","author":"Philpott","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B93","doi-asserted-by":"publisher","first-page":"e519","DOI":"10.1128\/AAC.00583-19","article-title":"A guide to understanding antimicrobial drug dosing in critically ill patients on renal replacement therapy","volume":"63","author":"Pistolesi","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"B94","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s15010-012-0300-3","article-title":"Experience with daptomycin daily dosing in icu patients undergoing continuous renal replacement therapy","volume":"41","author":"Preiswerk","year":"2013","journal-title":"Infection"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s15010-019-01352-z","article-title":"Therapeutic drug monitoring-guided continuous infusion of piperacillin\/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience","volume":"47","author":"Richter","year":"2019","journal-title":"Infection"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1097\/CCM.0b013e318241e553","article-title":"Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study","volume":"40","author":"Roberts","year":"2012","journal-title":"Crit. Care Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1093\/jac\/dku177","article-title":"Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration","volume":"69","author":"Roberts","year":"2014","journal-title":"J. Antimicrob Chemother."},{"key":"B98","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13054-015-0818-8","article-title":"A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics","volume":"19","author":"Roberts","year":"2015","journal-title":"Crit. Care"},{"key":"B99","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa224","article-title":"The effect of renal replacement therapy and antibiotic dose on antibiotic concentrations in critically ill patients: data from the multinational smarrt study","volume-title":"Clin. Infect. Dis.","author":"Roberts","year":"2020"},{"key":"B100","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5301\/ijao.5000377","article-title":"Anti-infective drugs during continuous hemodialysis - using the bench to learn what to do at the bedside","volume":"38","author":"Roehr","year":"2015","journal-title":"Int. J. Artif. Organs"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1093\/jac\/dkw043","article-title":"Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients","volume":"71","author":"Roger","year":"2016","journal-title":"J. Antimicrob Chemother."},{"key":"B102","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1128\/AAC.00828-16","article-title":"Influence of renal replacement modalities on amikacin population pharmacokinetics in critically ill patients on continuous renal replacement therapy","volume":"60","author":"Roger","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"B103","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ijantimicag.2017.03.018","article-title":"Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients","volume":"50","author":"Roger","year":"2017","journal-title":"Int. J. Antimicrob Agents"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40262-016-0495-z","article-title":"Caspofungin population pharmacokinetics in critically ill patients undergoing continuous veno-venous haemofiltration or haemodiafiltration","volume":"56","author":"Roger","year":"2017","journal-title":"Clin. Pharmacokinet"},{"key":"B105","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1345\/aph.1Q437","article-title":"Pharmacokinetic assessment of peramivir in a hospitalized adult undergoing continuous venovenous hemofiltration","volume":"45","author":"Scheetz","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"B106","doi-asserted-by":"publisher","first-page":"R137","DOI":"10.1186\/cc10257","article-title":"Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy","volume":"15","author":"Seyler","year":"2011","journal-title":"Crit. Care"},{"key":"B107","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1053\/j.ackd.2017.05.004","article-title":"Antibiotic dosing in continuous renal replacement therapy","volume":"24","author":"Shaw","year":"2017","journal-title":"Adv. Chronic Kidney Dis."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.2215\/CJN.10260915","article-title":"Pharmacokinetics and pharmacodynamics of extended infusion versus short infusion piperacillin-tazobactam in critically ill patients undergoing crrt","volume":"11","author":"Shotwell","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01306-18","article-title":"Ex vivo characterization of effects of renal replacement therapy modalities and settings on pharmacokinetics of meropenem and vaborbactam","volume":"62","author":"Sime","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"B110","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ijantimicag.2018.07.008","article-title":"A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminaemia receiving continuous venovenous haemodiafiltration","volume":"52","author":"Sime","year":"2018","journal-title":"Int. J. Antimicrob Agents"},{"key":"B111","doi-asserted-by":"publisher","first-page":"e1619","DOI":"10.1128\/AAC.01655-19","article-title":"A population pharmacokinetic model-guided evaluation of ceftolozane-tazobactam dosing in critically ill patients undergoing continuous venovenous hemodiafiltration","volume":"64","author":"Sime","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/phar.2338","article-title":"Steady-state ceftazidime-avibactam serum concentrations and dosing recommendations in a critically ill patient being treated for pseudomonas aeruginosa pneumonia and undergoing continuous venovenous hemodiafiltration","volume":"39","author":"Soukup","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B113","doi-asserted-by":"publisher","first-page":"100","DOI":"10.2478\/jtim-2019-0022","article-title":"Treatment of ventilator-associated pneumonia with high-dose colistin under continuous veno-venous hemofiltration","volume":"7","author":"Spapen","year":"2019","journal-title":"J. Transl. Int. Med."},{"key":"B114","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1472-6904-11-11","article-title":"An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration","volume":"11","author":"Spooner","year":"2011","journal-title":"BMC Clin. Pharmacol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann. Intern Med."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/039139880803101206","article-title":"Ertapenem clearance during modeled continuous renal replacement therapy","volume":"31","author":"Stevenson","year":"2008","journal-title":"Int. J. Artif. Organs"},{"key":"B117","first-page":"303","article-title":"Pharmacokinetics and pharmacodynamics of biapenem in critically ill patients under continuous venovenous hemodiafiltration","volume":"61","author":"Suyama","year":"2008","journal-title":"Jpn J. Antibiot"},{"key":"B118","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.ijantimicag.2011.01.026","article-title":"Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy","volume":"37","author":"Taccone","year":"2011","journal-title":"Int. J. Antimicrob Agents"},{"key":"B119","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/jcph.432","article-title":"Pharmacokinetics of doripenem during high volume hemodiafiltration in patients with septic shock","volume":"55","author":"Tamme","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.chest.2018.09.004","article-title":"Continuous renal replacement therapy: who, when, why, and how","volume":"155","author":"Tandukar","year":"2019","journal-title":"Chest"},{"key":"B121","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1744-9987.2011.00914.x","article-title":"Removal of doripenem during hemodialysis and the optimum dosing regimen for patients undergoing hemodialysis","volume":"15","author":"Tanoue","year":"2011","journal-title":"Ther. Apher Dial"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.2169\/internalmedicine.56.8369","article-title":"A prospective study of the efficacy, safety and pharmacokinetics of enteral moxifloxacin in the treatment of hemodialysis patients with pneumonia","volume":"56","author":"Tokimatsu","year":"2017","journal-title":"Intern Med."},{"key":"B123","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1056\/NEJMct1206045","article-title":"Continuous renal-replacement therapy for acute kidney injury","volume":"367","author":"Tolwani","year":"2012","journal-title":"N Engl. J. Med."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1086\/444500","article-title":"Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy","volume":"41","author":"Trotman","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"B125","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International consensus guidelines for the optimal use of the polymyxins: endorsed by the american college of clinical pharmacy (accp), european society of clinical microbiology and infectious diseases (escmid), infectious diseases society of america (idsa), international society for anti-infective pharmacology (isap), society of critical care medicine (sccm), and society of infectious diseases pharmacists (sidp)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B126","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.1128\/AAC.00712-15","article-title":"Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements","volume":"59","author":"Ulldemolins","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1093\/jac\/dkv503","article-title":"Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements","volume":"71","author":"Ulldemolins","year":"2016","journal-title":"J. Antimicrob Chemother."},{"key":"B128","doi-asserted-by":"publisher","first-page":"196","DOI":"10.4212\/cjhp.v63i3.915","article-title":"Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis","volume":"63","author":"van de Vijsel","year":"2010","journal-title":"Can. J. Hosp Pharm."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1097\/CCM.0b013e3181d9d912","article-title":"High-dose renal replacement therapy for acute kidney injury: systematic review and meta-analysis","volume":"38","author":"Van Wert","year":"2010","journal-title":"Crit. Care Med."},{"key":"B130","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/jac\/dku413","article-title":"Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy","volume":"70","author":"Varghese","year":"2015","journal-title":"J. Antimicrob Chemother."},{"key":"B131","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/CCM.0b013e3181fa36fb","article-title":"Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis","volume":"39","author":"Vilay","year":"2011","journal-title":"Crit. Care Med."},{"key":"B132","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s13054-016-1551-7","article-title":"Effects of continuous renal replacement therapy on linezolid pharmacokinetic\/pharmacodynamics: a systematic review","volume":"20","author":"Villa","year":"2016","journal-title":"Crit. Care"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1128\/AAC.01801-15","article-title":"Doripenem treatment during continuous renal replacement therapy","volume":"60","author":"Vossen","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"B134","doi-asserted-by":"publisher","first-page":"e2416","DOI":"10.1128\/AAC.02425-16","article-title":"Micafungin plasma levels are not affected by continuous renal replacement therapy: experience in critically ill patients","volume":"61","author":"Vossen","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"B135","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s001340100857","article-title":"Pharmacokinetics of ciprofloxacin in icu patients on continuous veno-venous haemodiafiltration","volume":"27","author":"Wallis","year":"2001","journal-title":"Intensive Care Med."},{"key":"B136","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1128\/AAC.00335-13","article-title":"Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy","volume":"57","author":"Weiler","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"B137","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1128\/AAC.00464-17","article-title":"Pharmacokinetics and dialytic clearance of ceftazidime-avibactam in a critically ill patient on continuous venovenous hemofiltration","volume":"61","author":"Wenzler","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"B138","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/bf00199886","article-title":"Pharmacokinetics and dosage recommendations of teicoplanin in patients treated by continuous veno-venous haemodialysis (cvvhd)","volume":"46","author":"Wolter","year":"1994","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.coph.2015.07.003","article-title":"To increase or decrease dosage of antimicrobials in septic patients during continuous renal replacement therapy: the eternal doubt","volume":"24","author":"Wong","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1093\/jac\/dkaa028","article-title":"Population pharmacokinetics and dosing considerations of daptomycin in critically ill patients undergoing continuous renal replacement therapy","volume":"75","author":"Xie","year":"2020","journal-title":"J. Antimicrob Chemother."},{"key":"B141","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/bcp.13131","article-title":"Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy","volume":"83","author":"Xu","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1007\/s00134-003-1914-9","article-title":"Pharmacokinetics of teicoplanin in critically ill patients undergoing continuous hemodiafiltration","volume":"29","author":"Yagasaki","year":"2003","journal-title":"Intensive Care Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00786\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T19:08:31Z","timestamp":1616008111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00786\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":142,"alternative-id":["10.3389\/fphar.2020.00786"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.00786","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,29]]},"article-number":"786"}}